Dr. Gur Roshwalb
Partner, aMoon
Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts,
leads deals, manages the due diligence process, and sits on the boards of
AltruBio, Mina Therapeutics, and Viracta Therapeutics, aMoon Growth
portfolio companies. The aMoon Growth portfolio is a global portfolio,
based Israel, investing in the convergence of biology and technology.
Beginning his career as a practicing physician and Gur understands the
urgency driving the innovation in the healthcare industry. He moved to
Israel in 2019 to work with aMoon to accelerate HealthTech advances into
clinical practice.
Gur has over 20 years of healthcare industry and finance experience. Prior
to joining aMoon, he was CEO at several private and public biotech
companies. Earlier, Gur was a Vice President at Venrock, where he was an
investment professional on the healthcare team investing in both private
and public companies. Gur started his finance career at Piper Jaffray,
where he worked as a vice president and equity analyst, publishing research
on specialty pharmaceutical companies. Prior to Piper, Gur was in private
practice in New York following residency training in internal medicine at
Mount Sinai Medical Center, where he also served as Chief Resident.
Gur obtained his medical degree from Albert Einstein College of Medicine of
Yeshiva University, his MBA from the NYU Stern School of Business, and a
B.A. from Columbia University.